Screener / SEC EDGAR /CIK 0000730464 /10-K filed Aug 6, 2026, compared with Aug 7, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Consumer discretionary · Educational Services

Covista Inc. CVSA

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What CVSA's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Aug 6, 2026, CVSA reported $2.06 per share under GAAP and $2.09 on its own adjusted basis: the adjusted number is +2% above GAAP.

GAAP EPS $0.98, release Jan 31, 2024: Diluted earnings per share was $0.98, compared with $0.53 in the prior ● year Adjusted EPS $1.23, release Jan 31, 2024: Diluted earnings per share was $0.98, compared with $0.53 in the prior ● year; adjusted earnings per share was $1.23, compared with $1.17 in the prior year. +26% 2024-01 GAAP EPS $0.93, release May 2, 2024: Diluted earnings per share was $0.93, compared with $1.00 in the prior ● year Adjusted EPS $1.50, release May 2, 2024: Diluted earnings per share was $0.93, compared with $1.00 in the prior ● year; adjusted earnings per share was $1.50, compared with $1.13 in the prior year. +61% 2024-05 GAAP EPS $1.28, release Aug 6, 2024: Diluted earnings per share was $1.28, compared with $0.50 in the prior ● year Adjusted EPS $1.37, release Aug 6, 2024: Diluted earnings per share was $1.28, compared with $0.50 in the prior ● year; adjusted earnings per share was $1.37, compared with $1.03 in the prior year. +7% 2024-08 GAAP EPS $1.18, release Oct 29, 2024: Diluted earnings per share of $1.18, compared with $0.25 in the prior ● year Adjusted EPS $1.29, release Oct 29, 2024: Diluted earnings per share of $1.18, compared with $0.25 in the prior ● year; adjusted earnings per share of $1.29, compared with $0.93 in the prior year. +9% 2024-10 GAAP EPS $1.44, release Aug 7, 2025: Diluted earnings per share was $1.44, compared with $1.28 in the prior ● year Adjusted EPS $1.66, release Aug 7, 2025: Diluted earnings per share was $1.44, compared with $1.28 in the prior ● year; adjusted earnings per share was $1.66, compared with $1.37 in the prior year. +15% 2025-08 GAAP EPS $2.06, release Aug 6, 2026: Adjusted EPS $8.25, growth of 23.7% YoY Fourth quarter highlights ● GAAP diluted earnings per share $2.06 Adjusted EPS $2.09, release Aug 6, 2026: Adjusted EPS $8.25, growth of 23.7% YoY Fourth quarter highlights ● GAAP diluted earnings per share $2.06; adjusted EPS $2.09, up 25.9% year-over-year ● Total studen +2% 2026-08
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
Adjusted EPS $8.25, growth of 23.7% YoY Fourth quarter highlights ● GAAP diluted earnings per share $2.06 release
Adjusted EPS $8.25, growth of 23.7% YoY Fourth quarter highlights ● GAAP diluted earnings per share $2.06; adjusted EPS $2.09, up 25.9% year-over-year ● Total studen release

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Exhibit 99.1 Investor Contact:Jeremy Cohen [email protected] Media

Open on SEC

Exhibit 99.1 Investor Contact:Jeremy Cohen [email protected] Media Contact:Nick Lucido [email protected] Covista Reports First Quarter Fiscal Year 2027 Results; Raises Fiscal Year 2027 Revenue and Adjusted EPS Guidance Total enrollment up 7.6% YoY Revenue up 10.7% YoY Diluted earnings per share $1.95; Adjusted EPS $2.19, growth of 25.1% YoY Chief Financial Officer Robert Phelan announces planned retirement; will continue to serve until a successor is named First quarter highlights

● Total student enrollment of 104,713, up 7.6% year-over-year, achieved 13th straight quarter of growth

Chamberlain University achieved 3rd straight quarter of total enrollment ● growth and achieved 17th straight quarter of pre-licensure BSN total enrollment growth

Walden University achieved 13th straight quarter of total enrollment ● growth, up 12.8% year-over-year, highest total enrollment in university history

● Medical and Veterinary delivered total enrollment growth of 3.5% year-over-year

● GAAP net income $67.4 million; adjusted EBITDA $131.2 million, up 17.1% year-over-year

● Repriced our $510 million Term Loan B, reducing the interest rate margin by 25 basis points to SOFR plus 2.00%

Revenue in the range of $2,060 million to $2,095 million, or ● approximately 5.5% to 7% growth year-over-year, and from a previous range of $2,050 million to $2,090 million

Adjusted earnings per share in the range of $9.00 to $9.20, or ● approximately 9% to 11.5% growth year-over-year, and from a previous range of $8.90 to $9.15

CHICAGO – October 29, 2026 –Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported first quarter fiscal year 2027 results (ended Sep. 30, 2026). This quarter, the Company launched Purpose at Scale, its three-year strategy to train the next generation of healthcare professionals at industry-leading scale. Purpose at Scaleis underpinned by operational excellence, platform extension, employer integration and a technology focus. “ Purpose at Scaleis delivering and all four pillars of the strategy are contributing to our momentum. Total enrollment grew for the 13th consecutive quarter, powering our double-digit revenue growth and continued margin expansion. On that strength, we are raising our fiscal 2027 guidance,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “The demand behind our strategy is durable, and Covista is critical infrastructure for American healthcare. We serve an urgent need in the communities where care matters most, and by doing that well, we are strategically positioned to create lasting value for our shareholders.” Financial Highlights Selected financial data for the three months ended Sep. 30, 2026:

Operating income of $98.0 million, compared with $85.5 million in the ● prior year; adjusted operating income of $106.6 million, compared with $90.3 million in the prior year

Net income of $67.4 million, compared with $61.8 million in the prior ● year; adjusted net income of $75.8 million, compared with $64.9 million in the prior year

Diluted earnings per share of $1.95, compared with $1.67 in the prior ● year; adjusted earnings per share of $2.19, compared with $1.75 in the prior year

Adjusted EBITDA of $131.2 million, compared with $112.0 million in the ● prior year; adjusted EBITDA margin of 25.6%, compared with 24.2% in the prior year

Covista's strategic nursing collaboration with Advocate Health began ● enrolling students through Chamberlain University in Wisconsin. Building on that successful launch, the relationship is expanding to Chamberlain's three Chicago-area campuses.

Chamberlain University opened its Cincinnati and Salt Lake City campuses. ● The Company also announced it will open its 27th campus in Nashville, which is expected to begin classes in January 2027.

Walden University launched four new programs this quarter. Programs ● introduced heading into the 2026 academic year have already enrolled more than 2,000 students, demonstrating Walden’s speed to market in high-demand fields.

Covista released new analysis showing that students at Ross University ● School of Medicine and American University of the Caribbean School of Medicine passed the United States Medical Licensing Examination® (USMLE®) Step 1 on their first attempt at rates

comparable to or higher than U.S. MD students with similar MCAT scores in most score bands.¹

Covista’s performance and responsible business practices continued to ● earn national recognition, including TIME’s America’s Growth Leaders 2027 and World’s Best Companies 2026, and Newsweek’s America’s Greenest Companies 2027 and America’s Greatest Companies 2026.

● Total student enrollment increased 1.3% compared with the prior year, driven by growth in pre-licensure nursing.

● Total student enrollment increased 12.8% compared with the prior year, driven by growth in healthcare and non-healthcare programs.

● Total student enrollment increased 3.5% compared with the prior year, driven by growth in both medical and veterinary.

Fiscal Year 2027 Outlook Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year, to a range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth year-over-year.

Covista also raised its adjusted earnings per share guidance from a range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year, to a range of $9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year. Management Update Chief Financial Officer Robert Phelan has decided to retire from Covista after nearly seven years, as part of a planned transition. He will remain in this role until a successor is named, with no change in responsibilities. He will support the incoming Chief Financial Officer through a transition period. An active search is underway. Conference Call and Webcast Information Covista will hold a conference call to discuss its first quarter fiscal year 2027 results today at 4:00 p.m. CT (5:00 p.m. ET).

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13762351. The call will be simulcast through the Covista investor relations website at:https://investors.covista.com.

Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and supported by a community of 400,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit covista.com and follow us onLinkedIn,InstagramandYouTube. Cautionary Disclosure Regarding Forward-Looking Statements Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward- looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you. We cannot assure you that we will realize the results, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to us as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Covista's results in accordance with GAAP.

Comparison using university and AAMC data. Data is based on students who matriculated between 2021-2023 and sat for the USMLE Step 1 as of August 1. 2026. Not all matriculants sat for the USMLE Step 1 exam. Students must successfully matriculate, complete the Medical Sciences curriculum and pass a school approved Medical Sciences Comprehensive Exam to sit for the USMLE Step 1 exam.

2. Represents total students attending sessions during each institution’s most recent enrollment period in Q1 FY 2027 and Q1 FY 2026.

Covista Inc. Consolidated Statements of Income (unaudited) (in thousands, except per share data)

​ ​ ​ ​ Revenue Operating cost and expense: Cost of educational services Student services and administrative expense Restructuring expense Total operating cost and expense Operating income ​ ​ Interest expense 511,534 462,288 Other income, net ​ ​ Income from continuing 220,759 200,767 operations before income 192,585 175,734 taxes 163 310 Provision for income taxes 413,507 376,811 Income from continuing 98,027 85,477 operations (9,944) (11,090) Discontinued operations: 1,416 2,486 (Loss) income from 89,499 76,873 discontinued operations (18,017) (15,811) before income taxes 71,482 61,062 Benefit from income taxes ​ ​ (Loss) income from (5,420) ​ 747 discontinued operations 1,365 2025 23 Net income and ​ (4,055) ​ 770 comprehensive income Three Months Ended 67,427 ​ 61,832 ​ September 30, ​ ​ ​ Earnings (loss) per share: 2026 ​ ​ ​ Basic: ​ ​ ​ ​ ────────────────────────────────────────────────────────────────────────────── Continuing operations $ 2.11 $ 1.69 Discontinued operations $ -0.12 $ 0.02 Total basic earnings per $ 1.99 $ 1.71 share Diluted: ​ ​ Continuing operations $ 2.07 $ 1.65 Discontinued operations $ -0.12 $ 0.02 Total diluted earnings per $ 1.95 $ 1.67 share ​ ​ ​ ​ ​ Weighted-average shares ​ ​ ​ ​ outstanding: Basic shares ​ 33,951 ​ 36,111 Diluted shares ​ 34,573 ​ 37,057

​ ​ ​ Three Months Ended ​ September 30, ​ ​ 2026 ​ 2025 ​ Operating activities: ​ ​ ​ ​ ────────────────────────────────────────────────────────────────────────────── Net income $ 67,427 $ 61,832 Loss (income) from discontinued 4,055 -770 operations Income from continuing ​ 71,482 ​ 61,062 operations Adjustments to reconcile net income to net cash provided by ​ ​ operating activities: Stock-based compensation 8,181 8,293 Amortization of operating ​ 7,018 ​ 7,216 lease assets Depreciation 10,862 10,296 Amortization of acquired intangible 1,394 2,805 assets Amortization and write-off of debt ​ 660 ​ 1,145 discount and issuance costs Provision for credit losses ​ 22,402 ​ 14,883 Deferred income taxes 8,798 54,413 Loss on disposals and impairments of — 2 property and equipment Loss (gain) on investments ​ 218 ​ -680 Changes in assets and ​ ​ liabilities: Accounts and financing -94,219 -62,690 receivables Prepaid expenses and other current -10,788 -29,841 assets Cloud computing -3,292 -4,812 implementation assets Accounts payable -13,536 1,378 Accrued payroll and ​ -20,886 ​ -24,359 benefits Accrued liabilities 13,025 -12,287 Deferred revenue 107,928 109,082 Operating lease liabilities ​ 10,548 ​ -4,317 Other assets and -5,524 -960 liabilities Net cash provided by operating 114,271 130,629 activities-continuing operations Net cash used in operating activities-discontinued -233 -80 operations Net cash provided by operating 114,038 130,549 activities Investing activities: ​ ​ ​ Capital expenditures -37,592 -16,023 Proceeds from sales of marketable — 100 securities Purchases of marketable — -100 securities Net cash used in investing -37,592 -16,023 activities Financing activities: ​ ​ ​ Proceeds from exercise of — 131 stock options Employee taxes paid on withholding -16,203 -39,119 shares Proceeds from stock issued under 564 411 Colleague Stock Purchase Plan Repurchases of common stock -81,002 -7,595 for treasury Repayments under long-term debt -163,000 — obligations Payment of debt issuance — -3,333 costs Net cash used in financing -259,641 -49,505 activities Net (decrease) increase in cash, cash -183,195 65,021 equivalents and restricted cash Cash, cash equivalents and restricted 407,754 201,164 cash at beginning of period Cash, cash equivalents and restricted $ 224,559 $ 266,185 cash at end of period

Covista Inc. Non-GAAP Financial Measures and Reconciliations We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables: Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss (income) from discontinued operations. Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss (income) from discontinued operations. Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, and debt modification costs. Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock- based compensation, restructuring expense, strategic advisory costs, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income. Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures. Net debt – Defined as total long-term debt principal less cash and cash equivalents. Net leverage – Defined as net debt divided by adjusted EBITDA. A description of special items in our non-GAAP financial measures described above are as follows:

Restructuring expense primarily related to workforce reductions and prior ● real estate consolidations at Covista’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense.

Strategic advisory costs related to expanding capabilities and bringing ● new capacities to market to further enhance our strategic position. We do not include normal, recurring, cash operating expenses in our strategic advisory costs.

● Loss (income) from discontinued operations includes activity from ongoing litigation costs and settlements related to prior divestitures.

(1) Consolidated results include Home Office activities not allocated to segments.

(1) Consolidated results include Home Office activities not allocated to segments.

Covista Inc. Adjusted Earnings (unaudited) (in thousands, except per share data)

​ ​ ​ ​ ​ ​ Three Months Ended ​ September 30, ​ 2026 2025 Net income (GAAP) $ 67,427 $ 61,832 Restructuring expense ​ 163 ​ 310 Amortization of acquired intangible ​ 1,394 ​ 2,805 assets Strategic advisory costs ​ 6,231 ​ 1,684 Loss on debt extinguishment and debt ​ 756 ​ 295 modification costs U.S. tax benefit due to an increase in ​ -2,031 ​ — foreign-derived income Income tax impact on non-GAAP ​ -2,152 ​ -1,224 adjustments(1) Loss (income) from discontinued ​ 4,055 ​ -770 operations Adjusted net income (non-GAAP) $ 75,843 $ 64,932

(1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

​ ​ ​ ​ ​ ​ Three Months Ended ​ September 30, ​ 2026 2025 Diluted earnings per share $ 1.95 $ 1.67 (GAAP) Effect on diluted earnings per ​ ​ ​ ​ share: Restructuring expense ​ 0.00 ​ 0.01 Amortization of acquired intangible ​ 0.04 ​ 0.08 assets Strategic advisory costs ​ 0.18 ​ 0.05 Loss on debt extinguishment and debt ​ 0.02 ​ 0.01 modification costs U.S. tax benefit due to an increase in ​ -0.06 ​ - foreign-derived income Income tax impact on non-GAAP ​ -0.06 ​ -0.03 adjustments(1) Loss (income) from discontinued ​ 0.12 ​ -0.02 operations Adjusted earnings per share $ 2.19 $ 1.75 (non-GAAP) Diluted shares ​ 34,573 ​ 37,057

(1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

​ ​ ​ Twelve Months Ended ​ September 30, 2026 ​ ──────────────────────────────────────────────────────────────────── Covista: ​ ​ Net income (GAAP) $ 257,161 Loss from discontinued operations ​ 20,634 Interest expense ​ 44,289 Other income, net ​ -6,108 Provision for income taxes ​ 79,950 Depreciation and amortization ​ 73,836 Stock-based compensation ​ 41,104 Restructuring expense ​ 6,182 Strategic advisory costs ​ 23,109 Debt modification costs ​ 756 Adjusted EBITDA (non-GAAP) $ 540,913 ​ ​ ​ ​ September 30, 2026 Total long-term debt principal $ 510,000 Less: Cash and cash equivalents ​ -222,223 Net debt (non-GAAP) $ 287,777 ​ ​ ​ Net leverage (non-GAAP) ​ 0.5x

Full text with the tables
Exhibit 99.1 Investor Contact:Jeremy Cohen [email protected] Media
Contact:Nick Lucido [email protected] Covista Reports First Quarter
Fiscal Year 2027 Results; Raises Fiscal Year 2027 Revenue and Adjusted EPS
Guidance Total enrollment up 7.6% YoY Revenue up 10.7% YoY Diluted earnings per
share $1.95; Adjusted EPS $2.19, growth of 25.1% YoY Chief Financial Officer
Robert Phelan announces planned retirement; will continue to serve until a
successor is named First quarter highlights
                                                                                
  ●  Total student enrollment of 104,713, up 7.6% year-over-year, achieved      
     13th straight quarter of growth                                            
                                                                                
                                                         
  ●  Revenue of $511.5 million, up 10.7% year-over-year  
                                                         
                                                                                
     Chamberlain University achieved 3rd straight quarter of total enrollment   
  ●  growth and achieved 17th straight quarter of pre-licensure BSN total       
     enrollment growth                                                          
                                                                                
                                                                                
     Walden University achieved 13th straight quarter of total enrollment       
  ●  growth, up 12.8% year-over-year, highest total enrollment in university    
     history                                                                    
                                                                                
                                                                                
  ●  Medical and Veterinary delivered total enrollment growth of 3.5%           
     year-over-year                                                             
                                                                                
                                                                                
  ●  GAAP net income $67.4 million; adjusted EBITDA $131.2 million, up 17.1%    
     year-over-year                                                             
                                                                                
Capital allocation
                                                             
  ●  Repurchased $84 million of shares in the first quarter  
                                                             
                                               
  ●  Net leverage of 0.5x as of Sep. 30, 2026  
 ───────────────────────────────────────────── 
                                               
                                                                                
  ●  Repriced our $510 million Term Loan B, reducing the interest rate margin   
     by 25 basis points to SOFR plus 2.00%                                      
                                                                                
Increased fiscal year 2027 guidance
                                                                                
     Revenue in the range of $2,060 million to $2,095 million, or               
  ●  approximately 5.5% to 7% growth year-over-year, and from a previous range  
     of $2,050 million to $2,090 million                                        
                                                                                
                                                                                
     Adjusted earnings per share in the range of $9.00 to $9.20, or             
  ●  approximately 9% to 11.5% growth year-over-year, and from a previous       
     range of $8.90 to $9.15                                                    
                                                                                
CHICAGO – October 29, 2026 –Covista Inc. (NYSE: CVSA), America’s largest
healthcare educator, today reported first quarter fiscal year 2027 results
(ended Sep. 30, 2026). This quarter, the Company launched Purpose at Scale, its
three-year strategy to train the next generation of healthcare professionals at
industry-leading scale. Purpose at Scaleis underpinned by operational
excellence, platform extension, employer integration and a technology focus. “
Purpose at Scaleis delivering and all four pillars of the strategy are
contributing to our momentum. Total enrollment grew for the 13th consecutive
quarter, powering our double-digit revenue growth and continued margin
expansion. On that strength, we are raising our fiscal 2027 guidance,” said
Steve Beard, Chairman and Chief Executive Officer, Covista. “The demand behind
our strategy is durable, and Covista is critical infrastructure for American
healthcare. We serve an urgent need in the communities where care matters most,
and by doing that well, we are strategically positioned to create lasting value
for our shareholders.” Financial Highlights Selected financial data for the
three months ended Sep. 30, 2026:
                                                                             
  ●  Revenue of $511.5 million increased 10.7% compared with the prior year  
                                                                             
                                                                                
     Operating income of $98.0 million, compared with $85.5 million in the      
  ●  prior year;                                                                
     adjusted operating income of $106.6 million, compared with $90.3 million   
     in the prior year                                                          
                                                                                
                                                                                
     Net income of $67.4 million, compared with $61.8 million in the prior      
  ●  year;                                                                      
     adjusted net income of $75.8 million, compared with $64.9 million in the   
     prior year                                                                 
                                                                                
                                                                                
     Diluted earnings per share of $1.95, compared with $1.67 in the prior      
  ●  year;                                                                      
     adjusted earnings per share of $2.19, compared with $1.75 in the prior     
     year                                                                       
                                                                                
                                                                                
     Adjusted EBITDA of $131.2 million, compared with $112.0 million in the     
  ●  prior year;                                                                
     adjusted EBITDA margin of 25.6%, compared with 24.2% in the prior year     
                                                                                
Business Highlights
                                                                                
     Covista's strategic nursing collaboration with Advocate Health began       
  ●  enrolling students through Chamberlain University in Wisconsin. Building   
     on that successful launch, the relationship is expanding to Chamberlain's  
     three Chicago-area campuses.                                               
                                                                                
                                                                                
     Chamberlain University opened its Cincinnati and Salt Lake City campuses.  
  ●  The Company also announced it will open its 27th campus in Nashville,      
     which is expected to begin classes in January 2027.                        
                                                                                
                                                                                
     Walden University launched four new programs this quarter. Programs        
  ●  introduced heading into the 2026 academic year have already enrolled more  
     than 2,000 students, demonstrating Walden’s speed to market in             
     high-demand fields.                                                        
                                                                                
                                                                                
     Covista released new analysis showing that students at Ross University     
  ●  School of Medicine and American University of the Caribbean School of      
     Medicine passed the United States Medical Licensing Examination® (USMLE®)  
     Step 1 on their first attempt at rates                                     
                                                                                
                                                      
  comparable to or higher than U.S. MD students with  
  similar MCAT scores in most score bands.¹           
                                                      
                                                                                
     Covista’s performance and responsible business practices continued to      
  ●  earn national recognition, including TIME’s America’s Growth Leaders 2027  
     and World’s Best Companies 2026, and Newsweek’s America’s Greenest         
     Companies 2027 and America’s Greatest Companies 2026.                      
                                                                                
Segment Highlights Chamberlain
                                                                   
  ​                       ​                      ​        ​  ​          
  ​                       ​    Three Months Ended                    
  $ in millions          ​         September 30,                    
  ​                       ​ ​ ​                2026    2025  % Change  
  Revenue                ​                $192.4  $179.2  7.4%      
  Operating Income       ​                 $26.7   $25.6  4.4%      
  Adj. Operating Income  ​                 $26.7   $25.6  4.4%      
  Adj. EBITDA            ​                 $37.6   $35.1  7.1%      
  Total Students(2)      ​                40,351  39,846  1.3%      
                                                                   
                                                                                
  ●  Total student enrollment increased 1.3% compared with the prior year,      
     driven by growth in pre-licensure nursing.                                 
                                                                                
Walden
                                                                   
  ​                       ​                      ​        ​  ​          
  ​                       ​    Three Months Ended                    
  $ in millions          ​         September 30,                    
  ​                       ​ ​ ​                2026    2025  % Change  
  Revenue                ​                $216.7  $190.0  14.1%     
  Operating Income       ​                 $63.6   $53.3  19.5%     
  Adj. Operating Income  ​                 $65.0   $56.1  16.0%     
  Adj. EBITDA            ​                 $71.9   $61.9  16.1%     
  Total Students(2)      ​                58,881  52,216  12.8%     
                                                                   
                                                                                
  ●  Total student enrollment increased 12.8% compared with the prior year,     
     driven by growth in healthcare and non-healthcare programs.                
                                                                                
Medical and Veterinary
                                                                  
  ​                       ​                      ​       ​  ​          
  ​                       ​    Three Months Ended                   
  $ in millions          ​         September 30,                   
  ​                       ​ ​ ​                2026   2025  % Change  
  Revenue                ​                $102.5  $93.1  10.0%     
  Operating Income       ​                 $22.3  $16.7  33.0%     
  Adj. Operating Income  ​                 $22.3  $16.8  32.7%     
  Adj. EBITDA            ​                 $27.4  $21.4  27.9%     
  Total Students(2)      ​                 5,481  5,297  3.5%      
                                                                  
                                                                                
  ●  Total student enrollment increased 3.5% compared with the prior year,      
     driven by growth in both medical and veterinary.                           
                                                                                
Fiscal Year 2027 Outlook
Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050
million to $2,090 million, or approximately 5% to 7% growth year-over-year, to a
range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth
year-over-year.

Covista also raised its adjusted earnings per share guidance from a range of
$8.90 to $9.15, or approximately 8% to 11% growth year-over-year, to a range of
$9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year.
Management Update
Chief Financial Officer Robert Phelan has decided to retire from Covista after
nearly seven years, as part of a planned transition. He will remain in this role
until a successor is named, with no change in responsibilities. He will support
the incoming Chief Financial Officer through a transition period. An active
search is underway.
Conference Call and Webcast Information
Covista will hold a conference call to discuss its first quarter fiscal year
2027 results today at 4:00 p.m. CT (5:00 p.m. ET).

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1
201-389-0877 (international participants) and stating “Covista earnings call” or
by using conference ID:13762351. The call will be simulcast through the Covista
investor relations website at:https://investors.covista.com.

Covista will archive a replay of the call for 30 days. To access the replay,
dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID:
13762351, or visit the Covista investor relations website.
About Covista

Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000
students and supported by a community of 400,000 alumni across five accredited
institutions. Through personalized, tech-enabled education powered by 10,000
faculty and colleagues, Covista expands access to healthcare careers and
addresses the U.S. healthcare workforce shortage at scale. Covista is the parent
company of American University of the Caribbean School of Medicine, Chamberlain
University, Ross University School of Medicine, Ross University School of
Veterinary Medicine and Walden University. For more information, visit
covista.com and follow us onLinkedIn,InstagramandYouTube.
Cautionary Disclosure Regarding Forward-Looking Statements Certain statements
contained in this release are forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
provide current expectations of future events based on certain assumptions and
include any statement that does not directly relate to any historical or current
fact, which includes statements regarding Covista’s future growth. Forward-
looking statements generally can be identified by the use of forward-looking
terminology such as “future,” “believe,” “project,” “expect,” “anticipate,”
“estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,”
“continue,” “preliminary,” “potential,” “range,” and similar terms. These
forward-looking statements are subject to risk and uncertainties that could
cause actual results to differ materially from those described in the
statements. Important factors that could cause actual results to differ
materially from the expectations expressed or implied by our forward-looking
statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on
Form 10-K. You should evaluate forward-looking statements in the context of
these risks and uncertainties and are cautioned to not place undue reliance on
such forward-looking statements. We caution you that these factors may not
contain all of the factors that are important to you. We cannot assure you that
we will realize the results, performance or developments we expect or anticipate
or, even if substantially realized, that they will result in the consequences or
affect us or our operations in the way we expect. All forward-looking statements
are based on information available to us as of the date any such statements are
made, and Covista assumes no obligation to publicly update or revise its
forward-looking statements even if experience or future changes make it clear
that any projected results expressed or implied therein will not be realized,
except as required by law. A reconciliation of non-GAAP guidance measures to
corresponding GAAP measures is not available on a forward-looking basis without
unreasonable effort due to the uncertainty of special items that may be incurred
in the future, although these special items could be material to Covista's
results in accordance with GAAP.
                                                                                
      Comparison using university and AAMC data. Data is based on students who  
      matriculated between 2021-2023 and sat for the USMLE Step 1 as of August  
  1.  2026. Not all matriculants sat for the USMLE Step 1 exam. Students must   
      successfully matriculate, complete the Medical Sciences curriculum and    
      pass a school approved Medical Sciences Comprehensive Exam to sit for     
      the USMLE Step 1 exam.                                                    
                                                                                
                                                                                
  2.  Represents total students attending sessions during each institution’s    
      most recent enrollment period in Q1 FY 2027 and Q1 FY 2026.               
                                                                                
###

Covista Inc. Consolidated Balance Sheets (unaudited) (in thousands)
                                                                                
  ​                         ​    ​                            ​                     
  ​                         ​    September 30,               June 30,             
  ​                         ​ ​ ​  2026                    ​    2026               ​  
  Assets:                  ​    ​                        ​    ​                   ​  
  Current assets:          ​    ​                        ​    ​                   ​  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash            ​    $                222,223    $           406,316  
  equivalents                                                                   
  Restricted cash          ​                       2,336                  1,438  
  Accounts and financing   ​                     241,469                169,561  
  receivables, net                                                              
  Prepaid expenses and                                                          
  other current            ​                      86,542                 75,126  
  assets                                                                        
  Total current assets     ​                     552,570                652,441  
  Noncurrent assets:       ​                            ​                       ​  
  Property and equipment,  ​                     324,706                302,649  
  net                                                                           
  Operating lease assets   ​                     197,511                204,364  
  Intangible assets, net   ​                     752,860                754,254  
  Goodwill                 ​                     961,262                961,262  
  Other assets, net        ​                     139,364                137,738  
  Total noncurrent assets  ​                   2,375,703              2,360,267  
  Total assets             ​    $              2,928,273    $         3,012,708  
  Liabilities and          ​                            ​                       ​  
  shareholders' equity:                                                         
  Current liabilities:     ​                            ​                       ​  
  Accounts payable         ​    $                 96,383    $           124,763  
  Accrued payroll and      ​                      57,720                 78,669  
  benefits                                                                      
  Accrued liabilities      ​                     126,214                 94,364  
  Deferred revenue         ​                     365,096                259,125  
  Current operating lease  ​                      33,984                 34,799  
  liabilities                                                                   
  Current portion of       ​                       5,100                  5,100  
  long-term debt                                                                
  Total current            ​                     684,497                596,820  
  liabilities                                                                   
  Noncurrent liabilities:  ​                            ​                       ​  
  Long-term debt           ​                     495,131                657,750  
  Long-term operating      ​                     219,374                207,846  
  lease liabilities                                                             
  Deferred income taxes    ​                      69,320                 61,782  
  Other liabilities        ​                      38,308                 42,325  
  Total noncurrent         ​                     822,133                969,703  
  liabilities                                                                   
  Total liabilities        ​                   1,506,630              1,566,523  
  Commitments and          ​                            ​                       ​  
  contingencies                                                                 
  Total shareholders'      ​                   1,421,643              1,446,185  
  equity                                                                        
  Total liabilities and                                                         
  shareholders'            ​    $              2,928,273    $         3,012,708  
  equity                                                                        
                                                                                
Covista Inc. Consolidated Statements of Income (unaudited) (in thousands, except
per share data)
                                                                                
  ​                                                                              
  ​                                                                              
  ​                                                                              
  ​                                                                              
  Revenue                                                                       
  Operating cost and                                                            
  expense:                                                                      
  Cost of educational                                                           
  services                                                                      
  Student services and                                                          
  administrative expense                                                        
  Restructuring expense                                                         
  Total operating cost and                                                      
  expense                                                                       
  Operating income                                          ​                  ​  
  Interest expense                                   511,534           462,288  
  Other income, net                                         ​                  ​  
  Income from continuing                             220,759           200,767  
  operations before income                           192,585           175,734  
  taxes                                                  163               310  
  Provision for income taxes                         413,507           376,811  
  Income from continuing                              98,027            85,477  
  operations                                         (9,944)          (11,090)  
  Discontinued operations:                             1,416             2,486  
  (Loss) income from                                  89,499            76,873  
  discontinued operations                           (18,017)          (15,811)  
  before income taxes                                 71,482            61,062  
  Benefit from income taxes                                 ​                  ​  
  (Loss) income from                                 (5,420)    ​           747  
  discontinued operations                              1,365    2025        23  
  Net income and                ​                     (4,055)    ​           770  
  comprehensive income          Three Months Ended    67,427    ​        61,832  
  ​                              September 30,               ​    ​              ​  
  Earnings (loss) per share:    2026                        ​    ​              ​  
  Basic:                        ​                            ​    ​              ​  
 ────────────────────────────────────────────────────────────────────────────── 
  Continuing operations         $                       2.11    $         1.69  
  Discontinued operations       $                      -0.12    $         0.02  
  Total basic earnings per      $                       1.99    $         1.71  
  share                                                                         
  Diluted:                                                  ​                  ​  
  Continuing operations         $                       2.07    $         1.65  
  Discontinued operations       $                      -0.12    $         0.02  
  Total diluted earnings per    $                       1.95    $         1.67  
  share                                                                         
  ​                              ​                            ​    ​              ​  
  Weighted-average shares       ​                            ​    ​              ​  
  outstanding:                                                                  
  Basic shares                  ​                      33,951    ​        36,111  
  Diluted shares                ​                      34,573    ​        37,057  
                                                                                
Covista Inc. Consolidated Statements of Cash Flows (unaudited) (in thousands)
                                                                                
  ​                               ​                                               
  ​                               Three Months Ended                             
  ​                               September 30,                   ​               
  ​                               2026                        ​    2025         ​  
  Operating activities:          ​                            ​    ​             ​  
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                     $                     67,427    $      61,832  
  Loss (income) from                                                            
  discontinued                                          4,055             -770  
  operations                                                                    
  Income from continuing         ​                      71,482    ​       61,062  
  operations                                                                    
  Adjustments to reconcile                                                      
  net income to                                                                 
  net cash provided by                                       ​                 ​  
  operating                                                                     
  activities:                                                                   
  Stock-based compensation                              8,181            8,293  
  Amortization of operating      ​                       7,018    ​        7,216  
  lease assets                                                                  
  Depreciation                                         10,862           10,296  
  Amortization of acquired                                                      
  intangible                                            1,394            2,805  
  assets                                                                        
  Amortization and write-off                                                    
  of debt                        ​                         660    ​        1,145  
  discount and issuance costs                                                   
  Provision for credit losses    ​                      22,402    ​       14,883  
  Deferred income taxes                                 8,798           54,413  
  Loss on disposals and                                                         
  impairments of                                            —                2  
  property and equipment                                                        
  Loss (gain) on investments     ​                         218    ​         -680  
  Changes in assets and                                      ​                 ​  
  liabilities:                                                                  
  Accounts and financing                              -94,219          -62,690  
  receivables                                                                   
  Prepaid expenses and other                                                    
  current                                             -10,788          -29,841  
  assets                                                                        
  Cloud computing                                      -3,292           -4,812  
  implementation assets                                                         
  Accounts payable                                    -13,536            1,378  
  Accrued payroll and            ​                     -20,886    ​      -24,359  
  benefits                                                                      
  Accrued liabilities                                  13,025          -12,287  
  Deferred revenue                                    107,928          109,082  
  Operating lease liabilities    ​                      10,548    ​       -4,317  
  Other assets and                                     -5,524             -960  
  liabilities                                                                   
  Net cash provided by                                                          
  operating                                           114,271          130,629  
  activities-continuing                                                         
  operations                                                                    
  Net cash used in operating                                                    
  activities-discontinued                                -233              -80  
  operations                                                                    
  Net cash provided by                                                          
  operating                                           114,038          130,549  
  activities                                                                    
  Investing activities:                                      ​    ​             ​  
  Capital expenditures                                -37,592          -16,023  
  Proceeds from sales of                                                        
  marketable                                                —              100  
  securities                                                                    
  Purchases of marketable                                   —             -100  
  securities                                                                    
  Net cash used in investing                          -37,592          -16,023  
  activities                                                                    
  Financing activities:                                      ​    ​             ​  
  Proceeds from exercise of                                 —              131  
  stock options                                                                 
  Employee taxes paid on                                                        
  withholding                                         -16,203          -39,119  
  shares                                                                        
  Proceeds from stock issued                                                    
  under                                                   564              411  
  Colleague Stock Purchase                                                      
  Plan                                                                          
  Repurchases of common stock                         -81,002           -7,595  
  for treasury                                                                  
  Repayments under long-term                                                    
  debt                                               -163,000                —  
  obligations                                                                   
  Payment of debt issuance                                  —           -3,333  
  costs                                                                         
  Net cash used in financing                         -259,641          -49,505  
  activities                                                                    
  Net (decrease) increase in                                                    
  cash, cash                                         -183,195           65,021  
  equivalents and restricted                                                    
  cash                                                                          
  Cash, cash equivalents and                                                    
  restricted                                          407,754          201,164  
  cash at beginning of period                                                   
  Cash, cash equivalents and                                                    
  restricted                     $                    224,559    $     266,185  
  cash at end of period                                                         
                                                                                
Covista Inc. Segment Revenue (unaudited) (in thousands)
                                                                                
                     ​                                                           
                Three                                                           
               Months                                                           
  ​        ​      Ended                                                        ​   
  ​        ​    Septem…                                                        ​   
  ​        ​        30,         ​        ​         ​  ​    ​                        ​   
  ​        ​           ​         ​        ​         ​  ​    Incre…        ​        ​  ​   
 ────────────────────────────────────────────────────────────────────────────── 
  ​        ​ ​ ​     2026             2025           ​ ​ ​  $                    %  ​   
  Reven…  ​           ​         ​        ​         ​  ​    ​              ​        ​  ​   
  Chamb…  ​          $  192,400       $  179,201  ​    $       13,199     7.4  %  
  Walden  ​           ​  216,673        ​  189,960  ​    ​        26,713    14.1  %  
  Medic…                                                                        
  and     ​           ​  102,461        ​   93,127  ​    ​         9,334    10.0  %  
  Veter…                                                                        
  Conso…  ​          $  511,534       $  462,288  ​    $       49,246    10.7  %  
                                                                                
Covista Inc. Non-GAAP Financial Measures and Reconciliations We believe that
certain non-GAAP financial measures provide investors with useful supplemental
information regarding the underlying business trends and performance of
Covista’s ongoing operations as seen through the eyes of management and are
useful for period-over-period comparisons. We use these supplemental non-GAAP
financial measures internally in our assessment of performance and budgeting
process. However, these non-GAAP financial measures should not be considered as
a substitute for, or superior to, measures of financial performance prepared in
accordance with GAAP. The following are non-GAAP financial measures used in the
subsequent GAAP to non-GAAP reconciliation tables: Adjusted net income (most
comparable GAAP measure: net income) – Measure of Covista’s net income adjusted
for restructuring expense, amortization of acquired intangible assets, strategic
advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax
benefit due to an increase in foreign-derived income, and loss (income) from
discontinued operations. Adjusted earnings per share (most comparable GAAP
measure: diluted earnings per share) – Measure of Covista’s diluted earnings per
share adjusted for restructuring expense, amortization of acquired intangible
assets, strategic advisory costs, loss on debt extinguishment, debt modification
costs, U.S. tax benefit due to an increase in foreign-derived income, and loss
(income) from discontinued operations. Adjusted operating income (most
comparable GAAP measure: operating income) – Measure of Covista’s operating
income adjusted for restructuring expense, amortization of acquired intangible
assets, strategic advisory costs, and debt modification costs. Adjusted EBITDA
(most comparable GAAP measure: net income) – Measure of Covista’s net income
adjusted for loss (income) from discontinued operations, interest expense, other
income, net, provision for income taxes, depreciation, amortization of acquired
intangible assets, amortization of cloud computing implementation assets, stock-
based compensation, restructuring expense, strategic advisory costs, and debt
modification costs. Provision for income taxes, interest expense, and other
income, net are not recorded at the reportable segments, and therefore, the
segment adjusted EBITDA reconciliations begin with adjusted operating income.
Free cash flow (most comparable GAAP measure: net cash provided by operating
activities-continuing operations) – Defined as net cash provided by operating
activities-continuing operations less capital expenditures. Net debt – Defined
as total long-term debt principal less cash and cash equivalents. Net leverage –
Defined as net debt divided by adjusted EBITDA. A description of special items
in our non-GAAP financial measures described above are as follows:
                                                                                
     Restructuring expense primarily related to workforce reductions and prior  
  ●  real estate consolidations at Covista’s home office. We do not include     
     normal, recurring, cash operating expenses in our restructuring expense.   
                                                                                
                                                  
  ●  Amortization of acquired intangible assets.  
                                                  
                                                             
  ●  Amortization of cloud computing implementation assets.  
                                                             
                                                                                
     Strategic advisory costs related to expanding capabilities and bringing    
  ●  new capacities to market to further enhance our strategic position. We do  
     not include normal, recurring, cash operating expenses in our strategic    
     advisory costs.                                                            
                                                                                
                                                                            
  ●  Loss on debt extinguishment related to the amendment of the Revolver.  
                                                                            
                                                                      
  ●  Debt modification costs related to refinancing our Term Loan B.  
                                                                      
                                                                     
  ●  U.S. tax benefit due to an increase in foreign-derived income.  
                                                                     
                                                                                
  ●  Loss (income) from discontinued operations includes activity from ongoing  
     litigation costs and settlements related to prior divestitures.            
                                                                                
Covista Inc. Adjusted Operating Income (unaudited) (in thousands)
                                                                                
                     ​                                                           
                Three                                                           
               Months                                                           
  ​              Ended                                                        ​   
  ​           Septemb…                                                        ​   
  ​                30,         ​  ​       ​        ​  ​   ​                         ​   
  ​                   ​         ​  ​       ​        ​  ​   Increa…        ​        ​  ​   
 ────────────────────────────────────────────────────────────────────────────── 
  ​               2026           ​   2025          ​   $                     %  ​   
  Chambe…            ​         ​  ​       ​        ​  ​   ​               ​        ​  ​   
  Operat…           $   26,730  ​      $  25,608  ​   $         1,122     4.4  %  
  income                                                                        
  Adjust…                                                                       
  operat…           $   26,730  ​      $  25,608  ​   $         1,122     4.4  %  
  income                                                                        
  Operat…            ​     13.9  %      ​    14.3  %  ​               ​        ​  ​   
  margin                                                                        
  Adjust…                                                                       
  operat…            ​     13.9  %      ​    14.3  %  ​               ​        ​  ​   
  margin                                                                        
  ​                   ​         ​  ​       ​        ​  ​   ​               ​        ​  ​   
  Walden:            ​         ​  ​       ​        ​  ​   ​               ​        ​  ​   
  Operat…           $   63,649  ​      $  53,269  ​   $        10,380    19.5  %  
  income                                                                        
  Amorti…                                                                       
  of                                                                            
  acquir…            ​    1,394  ​       ​   2,805  ​   ​         -1,411        ​  ​   
  intang…                                                                       
  assets                                                                        
  Adjust…                                                                       
  operat…           $   65,043  ​      $  56,074  ​   $         8,969    16.0  %  
  income                                                                        
  Operat…            ​     29.4  %      ​    28.0  %  ​               ​        ​  ​   
  margin                                                                        
  Adjust…                                                                       
  operat…            ​     30.0  %      ​    29.5  %  ​               ​        ​  ​   
  margin                                                                        
  ​                   ​         ​  ​       ​        ​  ​   ​               ​        ​  ​   
  Medical                                                                       
  and                ​         ​  ​       ​        ​  ​   ​               ​        ​  ​   
  Veteri…                                                                       
  Operat…           $   22,251  ​      $  16,728  ​   $         5,523    33.0  %  
  income                                                                        
  Restru…            ​        —  ​       ​      44  ​   ​            -44        ​  ​   
  expense                                                                       
  Adjust…                                                                       
  operat…           $   22,251  ​      $  16,772  ​   $         5,479    32.7  %  
  income                                                                        
  Operat…            ​     21.7  %      ​    18.0  %  ​               ​        ​  ​   
  margin                                                                        
  Adjust…                                                                       
  operat…            ​     21.7  %      ​    18.0  %  ​               ​        ​  ​   
  margin                                                                        
  ​                   ​         ​  ​       ​        ​  ​   ​               ​        ​  ​   
  Covist…            ​         ​  ​       ​        ​  ​   ​               ​        ​  ​   
  Operat…                                                                       
  income            $   98,027  ​      $  85,477  ​   $        12,550    14.7  %  
  (GAAP)                                                                        
  Restru…            ​      163  ​       ​     310  ​   ​           -147        ​  ​   
  expense                                                                       
  Amorti…                                                                       
  of                                                                            
  acquir…            ​    1,394  ​       ​   2,805  ​   ​         -1,411        ​  ​   
  intang…                                                                       
  assets                                                                        
  Strate…                                                                       
  adviso…            ​    6,231  ​       ​   1,684  ​   ​          4,547        ​  ​   
  costs                                                                         
  Debt                                                                          
  modifi…            ​      756  ​       ​       —  ​   ​            756        ​  ​   
  costs                                                                         
  Adjust…                                                                       
  operat…           $  106,571  ​      $  90,276  ​   $        16,295    18.1  %  
  income                                                                        
  (non-G…                                                                       
  Operat…                                                                       
  margin             ​     19.2  %      ​    18.5  %  ​               ​        ​  ​   
  (GAAP)                                                                        
  Adjust…                                                                       
  operat…            ​     20.8  %      ​    19.5  %  ​               ​        ​  ​   
  margin                                                                        
  (non-G…                                                                       
                                                                                
(1) Consolidated results include Home Office activities not allocated to
segments.

Covista Inc. Adjusted EBITDA (unaudited) (in thousands)
                                                                                
                    ​                                                            
               Three                                                            
              Months                                                            
  ​             Ended                                                         ​   
  ​          Septemb…                                                         ​   
  ​               30,         ​  ​       ​         ​  ​   ​                         ​   
  ​                  ​         ​  ​       ​         ​  ​   Increa…        ​        ​  ​   
 ────────────────────────────────────────────────────────────────────────────── 
  ​              2026           ​   2025           ​   $                     %  ​   
  Chamb…            ​         ​  ​       ​         ​  ​   ​               ​        ​  ​   
  Adjus…                                                                        
  opera…           $   26,730  ​      $   25,608  ​   $         1,122     4.4  %  
  income                                                                        
  (GAAP)                                                                        
  Depre…            ​    6,094  ​       ​    5,375  ​   ​            719        ​  ​   
  Amort…                                                                        
  of                                                                            
  cloud             ​    2,386  ​       ​    1,527  ​   ​            859        ​  ​   
  compu…                                                                        
  imple…                                                                        
  assets                                                                        
  Stock…            ​    2,372  ​       ​    2,570  ​   ​           -198        ​  ​   
  compe…                                                                        
  Adjus…                                                                        
  EBITDA           $   37,582  ​      $   35,080  ​   $         2,502     7.1  %  
  (non-…                                                                        
  Adjus…                                                                        
  EBITDA            ​     19.5  %      ​     19.6  %  ​               ​        ​  ​   
  margin                                                                        
  (non-…                                                                        
  ​                  ​         ​  ​       ​         ​  ​   ​               ​        ​  ​   
  Walde…            ​         ​  ​       ​         ​  ​   ​               ​        ​  ​   
  Adjus…                                                                        
  opera…           $   65,043  ​      $   56,074  ​   $         8,969    16.0  %  
  income                                                                        
  (GAAP)                                                                        
  Depre…            ​    1,784  ​       ​    1,940  ​   ​           -156        ​  ​   
  Amort…                                                                        
  of                                                                            
  cloud             ​    2,253  ​       ​    1,204  ​   ​          1,049        ​  ​   
  compu…                                                                        
  imple…                                                                        
  assets                                                                        
  Stock…            ​    2,782  ​       ​    2,653  ​   ​            129        ​  ​   
  compe…                                                                        
  Adjus…                                                                        
  EBITDA           $   71,862  ​      $   61,871  ​   $         9,991    16.1  %  
  (non-…                                                                        
  Adjus…                                                                        
  EBITDA            ​     33.2  %      ​     32.6  %  ​               ​        ​  ​   
  margin                                                                        
  (non-…                                                                        
  ​                  ​         ​  ​       ​         ​  ​   ​               ​        ​  ​   
  Medic…                                                                        
  and               ​         ​  ​       ​         ​  ​   ​               ​        ​  ​   
  Veter…                                                                        
  Adjus…                                                                        
  opera…           $   22,251  ​      $   16,772  ​   $         5,479    32.7  %  
  income                                                                        
  (GAAP)                                                                        
  Depre…            ​    2,823  ​       ​    2,820  ​   ​              3        ​  ​   
  Amort…                                                                        
  of                                                                            
  cloud             ​      931  ​       ​      411  ​   ​            520        ​  ​   
  compu…                                                                        
  imple…                                                                        
  assets                                                                        
  Stock…            ​    1,390  ​       ​    1,410  ​   ​            -20        ​  ​   
  compe…                                                                        
  Adjus…                                                                        
  EBITDA           $   27,395  ​      $   21,413  ​   $         5,982    27.9  %  
  (non-…                                                                        
  Adjus…                                                                        
  EBITDA            ​     26.7  %      ​     23.0  %  ​               ​        ​  ​   
  margin                                                                        
  (non-…                                                                        
  ​                  ​         ​  ​       ​         ​  ​   ​               ​        ​  ​   
  Covis…            ​         ​  ​       ​         ​  ​   ​               ​        ​  ​   
  Net                                                                           
  income           $   67,427  ​      $   61,832  ​   $         5,595     9.0  %  
  (GAAP)                                                                        
  Loss                                                                          
  (inco…                                                                        
  from              ​    4,055  ​       ​     -770  ​   ​          4,825        ​  ​   
  disco…                                                                        
  opera…                                                                        
  Inter…            ​    9,944  ​       ​   11,090  ​   ​         -1,146        ​  ​   
  expen…                                                                        
  Other                                                                         
  incom…            ​   -1,416  ​       ​   -2,486  ​   ​          1,070        ​  ​   
  net                                                                           
  Provi…                                                                        
  for               ​   18,017  ​       ​   15,811  ​   ​          2,206        ​  ​   
  income                                                                        
  taxes                                                                         
  Depre…                                                                        
  and               ​   17,826  ​       ​   16,243  ​   ​          1,583        ​  ​   
  amort…                                                                        
  Stock…            ​    8,181  ​       ​    8,293  ​   ​           -112        ​  ​   
  compe…                                                                        
  Restr…            ​      163  ​       ​      310  ​   ​           -147        ​  ​   
  expen…                                                                        
  Strat…                                                                        
  advis…            ​    6,231  ​       ​    1,684  ​   ​          4,547        ​  ​   
  costs                                                                         
  Debt                                                                          
  modif…            ​      756  ​       ​        —  ​   ​            756        ​  ​   
  costs                                                                         
  Adjus…                                                                        
  EBITDA           $  131,184  ​      $  112,007  ​   $        19,177    17.1  %  
  (non-…                                                                        
  Adjus…                                                                        
  EBITDA            ​     25.6  %      ​     24.2  %  ​               ​        ​  ​   
  margin                                                                        
  (non-…                                                                        
                                                                                
(1) Consolidated results include Home Office activities not allocated to
segments.

Covista Inc. Adjusted Earnings (unaudited) (in thousands, except per share data)
                                                                                
  ​                                                    ​        ​        ​        ​  
  ​                                  Three Months Ended                          
  ​                                       September 30,                          
  ​                                                2026            2025          
  Net income (GAAP)                                  $  67,427       $  61,832  
  Restructuring expense                               ​     163        ​     310  
  Amortization of acquired                                                      
  intangible                                          ​   1,394        ​   2,805  
  assets                                                                        
  Strategic advisory costs                            ​   6,231        ​   1,684  
  Loss on debt extinguishment                                                   
  and debt                                            ​     756        ​     295  
  modification costs                                                            
  U.S. tax benefit due to an                                                    
  increase in                                         ​  -2,031        ​       —  
  foreign-derived income                                                        
  Income tax impact on non-GAAP                       ​  -2,152        ​  -1,224  
  adjustments(1)                                                                
  Loss (income) from                                                            
  discontinued                                        ​   4,055        ​    -770  
  operations                                                                    
  Adjusted net income (non-GAAP)                     $  75,843       $  64,932  
                                                                                
                                                                                
  (1)  Represents the income tax impact of non-GAAP continuing operations       
       adjustments that is recognized in our GAAP financial statements.         
                                                                                
                                                                                
  ​                                                    ​        ​        ​        ​  
  ​                                  Three Months Ended                          
  ​                                       September 30,                          
  ​                                                2026            2025          
  Diluted earnings per share                         $    1.95       $    1.67  
  (GAAP)                                                                        
  Effect on diluted earnings per                      ​        ​        ​        ​  
  share:                                                                        
  Restructuring expense                               ​    0.00        ​    0.01  
  Amortization of acquired                                                      
  intangible                                          ​    0.04        ​    0.08  
  assets                                                                        
  Strategic advisory costs                            ​    0.18        ​    0.05  
  Loss on debt extinguishment                                                   
  and debt                                            ​    0.02        ​    0.01  
  modification costs                                                            
  U.S. tax benefit due to an                                                    
  increase in                                         ​   -0.06        ​       -  
  foreign-derived income                                                        
  Income tax impact on non-GAAP                       ​   -0.06        ​   -0.03  
  adjustments(1)                                                                
  Loss (income) from                                                            
  discontinued                                        ​    0.12        ​   -0.02  
  operations                                                                    
  Adjusted earnings per share                        $    2.19       $    1.75  
  (non-GAAP)                                                                    
  Diluted shares                                      ​  34,573        ​  37,057  
                                                                                
Note: May not sum due to rounding.
                                                                                
  (1)  Represents the income tax impact of non-GAAP continuing operations       
       adjustments that is recognized in our GAAP financial statements.         
                                                                                
Covista Inc. Free Cash Flow (unaudited) (in thousands)
                                                                                
         ​                                                                       
         Twel…                                                                  
         Mont…                                                                  
  ​       Ended          ​               ​              ​               ​            
  ​       FY26       ​    FY26       ​    FY26      ​    FY26       ​    FY27      ​  
  ​       ​         Q1    ​         Q2    ​        Q3    ​         Q4    ​        Q1  
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  ca…                                                                           
  pr…                                                                           
  by     $      374…    $     427,…    $     406…    $     470,…    $     454…  
  op…                                                                           
  ac…                                                                           
  op…                                                                           
  (G…                                                                           
  Ca…    ​       -55…    ​      -59,…    ​      -69…    ​      -77,…    ​      -99…  
  ex…                                                                           
  Fr…                                                                           
  ca…    $      318…    $     368,…    $     336…    $     393,…    $     355…  
  fl…                                                                           
  (n…                                                                           
                                                                                
Covista Inc. Net Leverage (unaudited) (in thousands)
                                                                      
  ​                                     ​                               
  ​                                     Twelve Months Ended            
  ​                                     September 30, 2026           ​  
 ──────────────────────────────────────────────────────────────────── 
  Covista:                             ​                             ​  
  Net income (GAAP)                    $                     257,161  
  Loss from discontinued operations    ​                       20,634  
  Interest expense                     ​                       44,289  
  Other income, net                    ​                       -6,108  
  Provision for income taxes           ​                       79,950  
  Depreciation and amortization        ​                       73,836  
  Stock-based compensation             ​                       41,104  
  Restructuring expense                ​                        6,182  
  Strategic advisory costs             ​                       23,109  
  Debt modification costs              ​                          756  
  Adjusted EBITDA (non-GAAP)           $                     540,913  
  ​                                     ​                             ​  
  ​                                     September 30, 2026             
  Total long-term debt principal       $                     510,000  
  Less: Cash and cash equivalents      ​                     -222,223  
  Net debt (non-GAAP)                  $                     287,777  
  ​                                     ​                             ​  
  Net leverage (non-GAAP)              ​                         0.5x  
                                                                      

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CVSA/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.